{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:38:21Z","timestamp":1770997101412,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":937,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1999,6]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>: Compared with currently available NSAIDs (which inhibit COX\u20101 and COX\u20102 isoforms of cyclooxy\u2010 genase), MK\u20100966 (a specific COX\u20102 inhibitor) is expected to cause less gastrointestinal toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>: To compare the effect on the upper gastrointestinal mucosae of a high dose of MK\u20100966 with that of conventional doses of ibuprofen and aspirin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Healthy subjects (<jats:italic>n<\/jats:italic>\u2003=\u2003170; age range 18\u201354\u2003years) with endoscopically normal gastric and duodenal mucosa were randomized to either MK\u20100966 250\u2003mg q.d. (<jats:italic>n<\/jats:italic>\u2003=\u200351), ibuprofen 800\u2003mg t.d.s. (<jats:italic>n<\/jats:italic>\u2003=\u200351), aspirin 650\u2003mg q.d.s. (<jats:italic>n<\/jats:italic>\u2003=\u200317), or placebo (<jats:italic>n<\/jats:italic>\u2003=\u200351) in this 7\u2010day, double\u2010blind, parallel\u2010group study. The mucosae were evaluated by endoscopy using a predefined scale; scores could range from 0 to 4. The primary end\u2010point was the percentage of subjects who developed a mucosal score \u2265\u20032 (i.e. the development of one or more erosions). To evaluate COX\u20101 activity, serum thromboxane B<jats:sub>2<\/jats:sub> levels were determined in a subset of the population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The percentage of subjects who developed a mucosal score \u2265\u20032 in the MK\u20100966 group (12%) was significantly lower (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001) than that in the ibuprofen (71%) and aspirin (94%) groups, and was similar to that in the placebo group (8%). Only ibuprofen and aspirin significantly (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001) reduced baseline thromboxane B<jats:sub>2<\/jats:sub> levels. All treatments were generally well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this acute short\u2010term endoscopic study, MK\u20100966 250\u2003mg q.d. (a dose at least 10 times higher than that demonstrated to reduce the signs and symptoms of osteoarthritis) produced significantly less gastrointestinal mucosal damage than either ibuprofen 800\u2003mg t.d.s. or aspirin 650\u2003mg q.d.s. and was comparable to placebo in this regard.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1999.00529.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:38:48Z","timestamp":1047353928000},"page":"761-767","source":"Crossref","is-referenced-by-count":135,"title":["Specific inhibition of cyclooxygenase\u20102 with MK\u20100966 is associated with less gastroduodenal damage than either aspirin or ibuprofen"],"prefix":"10.1111","volume":"13","author":[{"given":"F. L.","family":"Lanza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F.","family":"Rack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. J.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Bolognese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E.","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. R.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. E.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117060"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.16.7384"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"21438","DOI":"10.1016\/S0021-9258(19)36629-3","article-title":"Identification of a pharmacologically distinct prostaglandin H synthetase in cultured epithelial cells","volume":"267","author":"Holtzman MJ","year":"1992","journal-title":"J Biol Chem"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"11586","DOI":"10.1016\/S0021-9258(19)49951-1","article-title":"Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthetase in rat preovulatory follicles. Induction in vivo and in vitro","volume":"267","author":"Sirois J","year":"1992","journal-title":"J Biol Chem"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53294-4"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00025a007"},{"key":"e_1_2_6_8_2","first-page":"1531","article-title":"Pharmacology of a selective cyclooxygenase\u20102 inhibitor L\u2010745,337: a novel nonsteroidal anti\u2010inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach","volume":"274","author":"Chan C\u2010C","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_9_2","unstructured":"FlowerRJ MoncadaS VaneJR.Analgesic\u2010antipyretics and anti\u2010inflammatory agents: drugs employed in the treatment of gout. In: Gilman AG Goodman LS Rall TW Murad F. The Pharmacological Basis of Therapeutics. New York: MacMillan Publishing Company 1985: 674\u2013715."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01540567"},{"key":"e_1_2_6_11_2","first-page":"S85","article-title":"MK\u20100966, a highly selective COX\u20102 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6\u2010week placebo controlled study","volume":"40","author":"Ehrich E","year":"1997","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8690211"},{"key":"e_1_2_6_13_2","first-page":"1276","article-title":"Expression of cyclooxygenase\u20102 in human gastric carcinoma","volume":"57","author":"Ristim\u00e4ki A","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_6_14_2","first-page":"A1907","article-title":"Effects of a novel cyclooxygenase (COX)\u20102 inhibitor on gastric mucosal prostaglanding (PG) synthesis in healthy humans","volume":"91","author":"Cryer B","year":"1996","journal-title":"Am J Gastroenterol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1999.00529.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1999.00529.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1999.00529.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T01:21:00Z","timestamp":1694395260000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1999.00529.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1999,6]]}},"alternative-id":["10.1046\/j.1365-2036.1999.00529.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1999.00529.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,6]]}}}